Latest / Bloomberg Law / Bayer Sticks With Roundup Despite Losing Second Trial
Transcript
- 0:03Speaker 1: Welcome to the Bloomberg Law Podcast. I'm June Grosso. Every
- 0:07Speaker 1: day we bring you insight and analysis into the most
- 0:10Speaker 1: important legal news of the day. You can find more
- 0:13Speaker 1: episodes of the Bloomberg Law Podcast on Apple Podcasts, SoundCloud
- 0:18Speaker 1: and on Bloomberg dot com slash podcasts. Buyer has lost
- 0:22Speaker 1: a second trial over claims that it's round Up we'd
- 0:25Speaker 1: killer causes cancer, and it was a big loss. The
- 0:28Speaker 1: jury awarded eighty point three million dollars to Edwin Hardeman,
- 0:32Speaker 1: who sprayed the herbicide on his property for decades and
- 0:35Speaker 1: said it caused his non Hodgkins lymphoma. Seventy five million
- 0:39Speaker 1: of that award was punitive damages. Buyer plans to appeal
- 0:43Speaker 1: the verdict and vowed to keep defending round Up, which
- 0:46Speaker 1: it says is safe, as it faces more than eleven
- 0:49Speaker 1: thousand lawsuits joining me as Robert Hockett, a professor at
- 0:52Speaker 1: Cornell Law School, Bob, what did the jury find here? Oh? So, yeah,
- 0:58Speaker 1: it found a couple of things. Up. Of the first,
- 1:00Speaker 1: there's several questions that kind of combine in a case
- 1:03Speaker 1: like this, right, So the first sense to do with
- 1:05Speaker 1: whether indeed there is a significant cancer risk associated with
- 1:09Speaker 1: a particular product. Right. Another thing then is um was
- 1:13Speaker 1: there some kind of culpability on the part of the
- 1:16Speaker 1: firm in sort of failing to notify people of this
- 1:19Speaker 1: danger or failing to look into whether there was a danger,
- 1:21Speaker 1: failing to rectify it in some way. And then finally
- 1:24Speaker 1: a third question is what is the precise relation between
- 1:27Speaker 1: this sort of cancer causing agent within the round up
- 1:30Speaker 1: we'd killer in this case on the one hand, and
- 1:32Speaker 1: the particular plaintiff before the court on the other hand. Right, So,
- 1:36Speaker 1: what the court found um uh at the first phase
- 1:39Speaker 1: of the trial was that there is there does indeed
- 1:41Speaker 1: appear to be uh this significant cancer risk that comes
- 1:45Speaker 1: with round up. And what remains then to be decided
- 1:49Speaker 1: um was well, to what degree is the company culpable
- 1:52Speaker 1: right for not having um you know, not having done
- 1:55Speaker 1: more to prevent the danger from occurring, or for not
- 1:58Speaker 1: having done more to sort of warn the public about it. Now,
- 2:00Speaker 1: that wouldn't be Buyer itself, of course, that would have
- 2:02Speaker 1: been Monsanto. But Buyer, as the acquirer of mon Santo
- 2:05Speaker 1: last June, basically succeeds mon Santo to its own its liabilities.
- 2:11Speaker 1: Bob Buyer says, This verdict isn't a harbinger of others,
- 2:15Speaker 1: because each trial has different facts and legal circumstances. But
- 2:19Speaker 1: both juries found that round up caused cancer, and both
- 2:22Speaker 1: found punitive damages based on Monsanto's past conduct. So do
- 2:27Speaker 1: you agree with Buyer? UM? I think it's it's I
- 2:31Speaker 1: can see why it wants to say what it's saying
- 2:34Speaker 1: right now in order effectively, I think, to sort of
- 2:36Speaker 1: calm fears on the part of its investors who might
- 2:39Speaker 1: be worried that they're more liabilities, had more losses ahead,
- 2:42Speaker 1: and so it's trying to make a little bit less
- 2:43Speaker 1: worried I think about future liabilities and losses. UM. That
- 2:47Speaker 1: being said, UM, I really very much hope that Buyer
- 2:50Speaker 1: doesn't actually believe entirely what it's been saying, because if
- 2:54Speaker 1: it does, then that suggests that it's going to adopt
- 2:57Speaker 1: the strategy that I think is actually quite risky for
- 2:59Speaker 1: the company. And the reason for that, in turn is that, well,
- 3:02Speaker 1: you know, there does seem to be a pretty strong
- 3:04Speaker 1: case to be made or to the effect that UM
- 3:07Speaker 1: the chemical agent is indeed problematic. There also seems to
- 3:11Speaker 1: be a pretty strong case to the effect that Monsanto
- 3:13Speaker 1: tried to hide this fact. And what that means is
- 3:15Speaker 1: that the only question remaining for buyer is the kind
- 3:18Speaker 1: of plaintif by plaintiff question as to whether you know
- 3:20Speaker 1: this plaintiff was affected, or whether there's a causal relation
- 3:23Speaker 1: between this plaintiff's cancer and that agent, or that plaintiffs
- 3:26Speaker 1: cancer and the agents and so on, and there you
- 3:28Speaker 1: have a total crapshoot. It really depends on who the
- 3:30Speaker 1: plaintiffs are. But most plankets aren't going to bring cases
- 3:32Speaker 1: like this. It doesn't seem to be unless they can show,
- 3:35Speaker 1: you know, significant exposure to that chemical agent. And these
- 3:38Speaker 1: are just the first two cases out of about eleven thousand,
- 3:42Speaker 1: two hundred. According to Bloomberg Intelligence, the settlement value of
- 3:45Speaker 1: all round up cases could exceed five billion dollars. When
- 3:49Speaker 1: does buyer begin to feel real pressure to settle these cases?
- 3:54Speaker 1: I think I think it really it ought to be
- 3:57Speaker 1: feeling that pressure now, right. It ought to be reading
- 3:59Speaker 1: those previous decisions, I think very carefully. The one thing
- 4:02Speaker 1: that it seems to be hanging its hat on, and
- 4:04Speaker 1: maybe there are two things that's hanging its hat on.
- 4:06Speaker 1: So there's another trial coming up up in San Francisco
- 4:08Speaker 1: and Buyer appears to believe that the judge you will
- 4:10Speaker 1: be hearing or presiding over that trial is himself a
- 4:14Speaker 1: bit more skeptical about the claims of causation between the
- 4:17Speaker 1: chemical agents presence on the one hand and people's developing
- 4:20Speaker 1: cancer on the other. So Buyer seems to be very
- 4:22Speaker 1: much betting on a favorable ruling from that judge is
- 4:25Speaker 1: a little bit more skeptical about the causal link. If
- 4:28Speaker 1: that judge were not to sort of demonstrate that skepticism,
- 4:31Speaker 1: and if Buyer were to lose there, I would think
- 4:33Speaker 1: that would be the finally on the coffin for them,
- 4:35Speaker 1: and they would probably think, you know, decide that it's
- 4:37Speaker 1: prudence to go ahead and settle across the board. If
- 4:40Speaker 1: they win, I think it's probably still a bad idea
- 4:43Speaker 1: not to settle, but at least they might think of
- 4:45Speaker 1: themselves as being in the game a bit longer now.
- 4:47Speaker 1: About this verdict was punitive damages, meaning to punish the
- 4:52Speaker 1: company for conduct. What message was that jury sending to Buyer?
- 4:58Speaker 1: It was sort of telling Buyer that, you know, you
- 5:00Speaker 1: probably you might have done better in June too, have
- 5:03Speaker 1: paid a little bit more attention to the perspective liability
- 5:06Speaker 1: of liabilities of Monsanto before you bought it. My understanding
- 5:10Speaker 1: is that right before the acquisition, most of the attention
- 5:12Speaker 1: that was paid was paid to the regulatory concerns about
- 5:15Speaker 1: whether right that the purchase would be permitted, and in consequence,
- 5:18Speaker 1: I think there might have overlooked or maybe paid insufficient
- 5:22Speaker 1: attention to the potential liability risk that would be coming
- 5:25Speaker 1: along with Monsanto, because when you acquire a company like Monsanto,
- 5:29Speaker 1: you do, of course acquire the bad along with the good,
- 5:31Speaker 1: and they don't appear to have researched the bad quite
- 5:34Speaker 1: as thoroughly as they might have done, maybe again, because
- 5:36Speaker 1: they were preoccupied with whether it would be regulatorily allowed
- 5:39Speaker 1: for them to purchase it at all. Hardeman's trial was
- 5:42Speaker 1: split into two parts. It was a format that Buyer
- 5:45Speaker 1: thought would give it the best chance. This verdict was
- 5:48Speaker 1: less than the previous verdict, which was two nine million
- 5:51Speaker 1: dollars and then knocked down by a judge to seventy
- 5:54Speaker 1: eight point six. Is that random or is that the
- 5:57Speaker 1: result of the two phase trial? Did it work for buyer?
- 6:02Speaker 1: I'm inclined to think that it was random because buyer
- 6:04Speaker 1: was hoping for is they were hoping that if we
- 6:07Speaker 1: could kind of split up the well back up for
- 6:11Speaker 1: one second a twilight. This basically implicates all three of
- 6:14Speaker 1: the questions that I mentioned from the top right. Is
- 6:16Speaker 1: the agent itself a cancer causing agent? Is there a
- 6:19Speaker 1: cause of relation between the plaintiff's use of the chemical
- 6:22Speaker 1: on the one hand and getting the cancer on the other,
- 6:24Speaker 1: And then again, was there something problematic about the way
- 6:26Speaker 1: Montanto dealt with the problem? Um? I think generally when
- 6:30Speaker 1: all three of those things are loved together, the perception
- 6:32Speaker 1: is that, well, there's a tendency for people to think, well,
- 6:34Speaker 1: it all looks pretty bad, so let's just go ahead
- 6:37Speaker 1: and cut some slack to the plaintiff there was hoping.
- 6:40Speaker 1: I think that by splitting these things up, there might
- 6:42Speaker 1: be some real question about one of those questions, like,
- 6:46Speaker 1: for example, the causal relation between the plaintiff's injuries uh
- 6:49Speaker 1: and the presence of the agent in the In the roundup, Um,
- 6:52Speaker 1: that didn't work right that particular, that hope was not fulfilled.
- 6:57Speaker 1: And given that, given that the very reason that they
- 7:00Speaker 1: had for trying to get the split up turned out
- 7:02Speaker 1: not to be a very good reason at all, I
- 7:04Speaker 1: think it would be unwise for buyer to think that, well,
- 7:07Speaker 1: the fact that the verdict was a little bit lower
- 7:09Speaker 1: this time is itself the product of the you know,
- 7:11Speaker 1: sort of uh divvying up of the of the case
- 7:13Speaker 1: into distinct cases or distinct trials. So buyer is going
- 7:17Speaker 1: to appeal this verdict and appeal the verdict in August,
- 7:21Speaker 1: what are its chances on appeal besides getting the verdict
- 7:23Speaker 1: knocked down a little bit? I am myself skeptical that
- 7:27Speaker 1: there's much chance of getting those verdicts overturned or getting
- 7:31Speaker 1: those those things changed. And again, I think it's because
- 7:34Speaker 1: of the nature of the particular questions that were before
- 7:36Speaker 1: the court and the nature of the findings with respect
- 7:38Speaker 1: to those questions. There was nothing especially controversial or sort
- 7:42Speaker 1: of you know, out of the ordinary or you know,
- 7:44Speaker 1: outlier ish about those specific decisions, and it seems to
- 7:49Speaker 1: me that Buyer then ought to read those decisions as
- 7:52Speaker 1: indicating that it's really got an uphill climb if it's
- 7:55Speaker 1: going to try to decouple in people's minds the relation
- 7:58Speaker 1: between you know, the president of the alleged carcinogen and
- 8:02Speaker 1: roundup on the one hand, and people's actually acquiring cancer
- 8:06Speaker 1: or contracting cancer. On the other hand, all right, thanks Bob.
- 8:09Speaker 1: Maybe they want Buyer wants to consider Elizabeth Warren's proposal
- 8:13Speaker 1: to break up the Fireman Santo might be all right,
- 8:21Speaker 1: thanks so much. That's reliability. Okay, thank you. That's Robert Hoggett,
- 8:25Speaker 1: music professor at Cornell Law School. Thanks for listening to
- 8:29Speaker 1: the Bloomberg Law Podcast. You can subscribe and listen to
- 8:32Speaker 1: the show on Apple podcast, SoundCloud, and on Bloomberg dot
- 8:36Speaker 1: com slash podcast. I'm June Brosso. This is Bloomberg